Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Queen Mary University of London
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
1. Willingness to provide informed consent
2. Males aged 18 years and over
3. Histological confirmed recurrent/residual adenocarcinoma of the prostate with Gleason score following primary focal prostate cancer ablation therapy. Biopsy must have been performed within 6 months of screening for the study
4. Prior focal ablation therapy using either High Intensity Focused Ultrasound (HIFU), Cryotherapy, brachytherapy, electroporation or Photodynamic therapy
5. Serum Prostate Specific Antigen (PSA) must be below 20
6. Absence of metastatic disease
7. Life expectancy ≥ 10 years
8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
9. MRI imaging to suggest urinary sphincter has not been incorporated in prior ablation therapy
You may not be if
1. Serious co-existing medical illness such as chronic active autoimmune disease (within the last 6 months).
2. Other active malignancy over the last 5 years that has required systemic therapy excluding:
1. Adjuvant therapy in the curative setting
2. Non-melanoma skin cancer
3. superficial transitional cell carcinoma
3. No willingness to comply with the procedural requirements of this protocol
4. Coagulopathy/ Cirrhosis
5. Severe obesity defined as a BMI greater than 45
6. Inability to tolerate general anaesthesia
7. Prior pelvic fracture
8. Extensive tethering of the rectum caused by prior ablation therapy
Clareo Health | Robotic Surgery After Focal Ablation Therapy
